Xin Zhong Chang
Wang L, Hu X, Wang P, Shao Z. Integrative 3' Untranslated Region-Based Model to Identify Patients with Low Risk of Axillary Lymph Node Metastasis in Operable Triple-Negative Breast Cancer. Oncologist. 2019;24:22-30 pubmed publisher
..This is the first 3'UTR-based model that will help identify TNBC patients with low risk of nodal involvement who are most likely to benefit from exemption axillary surgery. ..
Liu Y, Jiang Y, Xu X, Hu X, Yu K, Shao Z. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer. Clin Cancer Res. 2016;22:1653-62 pubmed publisher
..The multigene signature we developed can accurately predict clinical outcome and benefit of taxane chemotherapy in TNBC patients. ..
Jiang Y, Liu Y, Xu X, Jin X, Hu X, Yu K, et al
. Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. Cancer Res. 2016;76:2105-14 pubmed publisher
..Cancer Res; 76(8); 2105-14. Â©2016 AACR. ..
Jiang Y, Ma D, Suo C, Shi J, Xue M, Hu X, et al
. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019;: pubmed publisher
..The comprehensive profile of TNBCs provided here will serve as a reference to further advance the understanding and precision treatment of TNBC. ..
Hao S, Zhao Y, Peng J, Ren F, Yang W, Yu K, et al
. Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis. Sci Rep. 2019;9:286 pubmed publisher
..601-1.481) or overall survival (HR = 0.727; 95% CI, 0.358-1.478). Survival analysis demonstrated no statistically significant difference between IMPC and IDC, indicating that proactive or radical clinical therapy is unnecessary. ..
Ren Y, Hao S, Jin X, Ye F, Gong Y, Jiang Y, et al
. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer. Breast. 2019;43:97-104 pubmed publisher
..Adjuvant chemotherapy improves recurrence-free survival in T1c TNBC patients but not in T1b. Anthracycline-based taxane-free regimens might be sufficient to achieve RFS benefits in T1N0M0 TNBC patients. ..
Wang L, Yao L, Zheng Y, Xu Q, Liu X, Hu X, et al
. Expression of autophagy-related proteins ATG5 and FIP200 predicts favorable disease-free survival in patients with breast cancer. Biochem Biophys Res Commun. 2015;458:816-22 pubmed publisher
..748 versus 0.680, P < 0.001) and 5 years (0.756 versus 0.699, P < 0.001). Collectively, our findings established the prognostic significance of ATG5 and FIP200 in patients with breast cancer. ..
Yu K, Jiang Y, Hao S, Shao Z. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer. BMC Med. 2015;13:254 pubmed publisher
..The majority of ER-/PgR+/HER2- phenotype breast cancers are basal-like and associated with a lower endocrine therapy sensitivity score. Additional studies are needed to validate these findings. ..
Xie G, Liu Y, Jiang Y, Shao Z. Epidemiology and survival outcomes of mucinous adenocarcinomas: A SEER population-based study. Sci Rep. 2018;8:6117 pubmed publisher
..We also revealed a series of prognostic factors of MACs, including tumor sites, tumor grade and tumor stage, which may improve the current understanding of the clinical and biological patterns of MACs. ..